黄芪甲苷诱导骨髓间充质干细胞治疗帕金森病的新思路

帕金森病（Parkinson’s disease，PD）是一种黑质神经元发生损伤坏死的中枢神经退行性疾病。现在以药物治疗为主要手段，现有药物主要作用在关键信号靶点以缓解病情，但未能彻底修复变性神经元。近几年细胞治疗技术逐渐渗入到临床试验，已然成为社会焦点。骨髓间充质干细胞（bone marrow mesenchymal stem cells，BMSCs）是一种成体多能干细胞，其自我增殖和多向分化能力已被公认。BMSCs 可以应用于PD 中以探索更加有效的治疗策略。黄芪甲苷是中药黄芪的特征成分，具有抗炎，抗氧化以及抗凋亡等活性作用。另外黄芪甲苷对神经干细胞具有保护作用，研究亦发现黄芪甲苷在PD 模型中发挥保护神经作用。该文就BMSCs 治疗PD 现状和黄芪甲苷对PD 治疗作用的研究进展作一综述，以此为基础提出了黄芪甲苷诱导骨髓间充质干细胞治疗帕金森病的新思路。

A New Idea of Astragaloside-Induced Bone Marrow Mesenchymal Stem Cells in the Treatment of Parkinson’s Disease

Parkinson’s disease （PD） is a kind of neurodegenerative diseases of the central nervous system in which substantia nigra neurons are damaged and necrotic. At present，PD is mainly treated with drugs which affect the key molecular in the pathogenesis of PD or signaling pathway to alleviate the disease，however，denatured neuron could not be completely repaired. In recent years，cell therapy technology has gradually infiltrated into clinical trials and became a social focus. Bone marrow mesenchymal stem cells（BMSCs），a kind of adult pluripotent stem cells，have self-proliferation and multi-directional differentiation capabilities and are applied to explore more effective strategies for PD treatment. Astragaloside IV，a characteristic component of traditional Chinese medicine Astragalus，possesses anti-inflammatory，anti-oxidative and antiapoptotic activities. What’s more，Astragaloside IV has a protective effect on neural stem cells，and the study demonstrated that Astragaloside IV plays a neuroprotective role in PD model. This article reviewed the research progress of BMSCs and Astragaloside IV in the treatment of PD. A new idea that Astragaloside IV induced BMSCs to treat PD is proposed based on above of conclusions.